抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 2295人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852768, encodeId=daab1852e68fa, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗, objectType=article, longId=218152, objectId=7266218152a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7266218152a9, replyNumber=0, likeNumber=72, createdTime=2022-03-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7266218152a9, moduleTitle=BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7266218152a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852602, encodeId=68c21852602d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, objectType=article, longId=206994, objectId=d418206994cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d418206994cd, replyNumber=0, likeNumber=69, createdTime=2021-08-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d418206994cd, moduleTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d418206994cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852641, encodeId=f7fb185264195, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, objectType=article, longId=210568, objectId=111721056885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111721056885, replyNumber=0, likeNumber=78, createdTime=2021-04-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111721056885, moduleTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=111721056885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852689, encodeId=eac31852689bb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AJG：阿司匹林和选择性 5-羟色胺再摄取抑制剂的联合使用可以降低结直肠癌风险, objectType=article, longId=213285, objectId=d7d021328529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7d021328529, replyNumber=0, likeNumber=61, createdTime=2021-08-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7d021328529, moduleTitle=AJG：阿司匹林和选择性 5-羟色胺再摄取抑制剂的联合使用可以降低结直肠癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7d021328529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852626, encodeId=af3e18526264a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, objectType=article, longId=209220, objectId=b2172092201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2172092201a, replyNumber=0, likeNumber=67, createdTime=2021-10-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2172092201a, moduleTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2172092201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852624, encodeId=635b185262447, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：口服JAK抑制剂abroctinib用于中重度特应性皮炎, objectType=article, longId=209011, objectId=43102090117d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43102090117d, replyNumber=0, likeNumber=85, createdTime=2022-01-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43102090117d, moduleTitle=NEJM：口服JAK抑制剂abroctinib用于中重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43102090117d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852828, encodeId=2efe185282849, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, objectType=article, longId=221539, objectId=ea642215396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea642215396a, replyNumber=0, likeNumber=53, createdTime=2022-10-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea642215396a, moduleTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea642215396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852740, encodeId=6eea1852e408d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=勤浩医药SHP2抑制剂GH21完成中美双报IND, objectType=article, longId=216513, objectId=c0e7216513c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7216513c3, replyNumber=0, likeNumber=68, createdTime=2022-01-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7216513c3, moduleTitle=勤浩医药SHP2抑制剂GH21完成中美双报IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7216513c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852594, encodeId=d24d18525947a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, objectType=article, longId=206376, objectId=d9952063e6c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9952063e6c2, replyNumber=0, likeNumber=68, createdTime=2021-10-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9952063e6c2, moduleTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9952063e6c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852667, encodeId=b7d6185266eed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=GUT: 质子泵抑制剂的使用可能会增加胃癌的发生率, objectType=article, longId=211697, objectId=bf1b21169e4b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1b21169e4b, replyNumber=0, likeNumber=82, createdTime=2021-09-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1b21169e4b, moduleTitle=GUT: 质子泵抑制剂的使用可能会增加胃癌的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1b21169e4b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852652, encodeId=3cc2185265285, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, objectType=article, longId=211116, objectId=6a65211116f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a65211116f9, replyNumber=0, likeNumber=59, createdTime=2022-03-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a65211116f9, moduleTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a65211116f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852692, encodeId=6d911852692ed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Stroke：接受选择性血清素再摄取抑制剂治疗的卒中患者骨折风险如何？, objectType=article, longId=213395, objectId=4a62213395fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a62213395fa, replyNumber=0, likeNumber=74, createdTime=2022-02-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a62213395fa, moduleTitle=Stroke：接受选择性血清素再摄取抑制剂治疗的卒中患者骨折风险如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a62213395fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852830, encodeId=99f21852830ba, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, objectType=article, longId=221252, objectId=69a622125247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a622125247, replyNumber=0, likeNumber=63, createdTime=2022-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a622125247, moduleTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a622125247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852714, encodeId=0edf1852e1402, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, objectType=article, longId=214645, objectId=1284214645f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1284214645f5, replyNumber=0, likeNumber=57, createdTime=2022-05-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1284214645f5, moduleTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1284214645f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852588, encodeId=6d0d1852588d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAMA：高血压患者不应因新冠肺炎因素停止血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂治疗, objectType=article, longId=205952, objectId=e622205952d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e622205952d6, replyNumber=0, likeNumber=94, createdTime=2021-06-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e622205952d6, moduleTitle=JAMA：高血压患者不应因新冠肺炎因素停止血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e622205952d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852596, encodeId=0d9a1852596d8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=57, createdTime=2021-07-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852799, encodeId=b5911852e99bd, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, objectType=article, longId=219913, objectId=119c21991317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119c21991317, replyNumber=0, likeNumber=61, createdTime=2021-12-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119c21991317, moduleTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119c21991317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852794, encodeId=35c31852e9452, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, objectType=article, longId=219505, objectId=2f0321950544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0321950544, replyNumber=0, likeNumber=52, createdTime=2022-01-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0321950544, moduleTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0321950544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852678, encodeId=533518526e808, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, objectType=article, longId=212480, objectId=b2a22124805f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2a22124805f, replyNumber=0, likeNumber=55, createdTime=2021-06-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2a22124805f, moduleTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2a22124805f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852657, encodeId=646a185265e19, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, objectType=article, longId=211270, objectId=a5bb2112e0e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5bb2112e0e5, replyNumber=0, likeNumber=73, createdTime=2022-01-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5bb2112e0e5, moduleTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5bb2112e0e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗

2022-03-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤

2021-08-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况

2021-04-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AJG：阿司匹林和选择性 5-羟色胺再摄取抑制剂的联合使用可以降低结直肠癌风险

2021-08-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！

2021-10-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：口服JAK抑制剂abroctinib用于中重度特应性皮炎

2022-01-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效

2022-10-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

勤浩医药SHP2抑制剂GH21完成中美双报IND

2022-01-04

智智灵药 (审核中...)

前往app查看评论内容

#抑制剂#

Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效

2021-10-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

GUT: 质子泵抑制剂的使用可能会增加胃癌的发生率

2021-09-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择

2022-03-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Stroke：接受选择性血清素再摄取抑制剂治疗的卒中患者骨折风险如何？

2022-02-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益

2022-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物

2022-05-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAMA：高血压患者不应因新冠肺炎因素停止血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂治疗

2021-06-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）

2021-07-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量

2021-12-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果

2022-01-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应

2021-06-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗

2022-01-18

科室
- - 订阅+
  - 更多科室
工具
服务